Literature DB >> 7066898

Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration.

A Rahman, N More, P S Schein.   

Abstract

The chronic cardiotoxicity of doxorubicin as a free drug or entrapped in positive and negative liposomes was morphologically evaluated in mice treated seven times i.v. at a dose of 4 mg/kg. Liposomes were composed of phosphatidylcholine, cholesterol, and stearylamine (positive charge) or phosphatidylserine (negative charge). Administration of free doxorubicin caused a pattern of cardiac damage characterized by loss of myofiber elements, mitochondrial damage, nuclear abnormalities, swollen and distended sarcoplasmic reticulum leading to vacuolization, and increasing myeloid body accumulation. Cardiac tissues of mice treated with doxorubicin entrapped in negatively charged liposomes demonstrated pronounced loss of filaments, enlarged mitochondria, disruptive loss of crests, and expanded nuclear membrane. However, electron microscopic examination of the cardiac muscles of mice treated with positive liposomes demonstrated a significant protection from drug-induced toxicity, with only minor loss of parallel fibrillar arrangement and myofilaments in limited focal areas. The majority of the tissue demonstrated normal vasculature and intercalation of myocytes as compared to control groups. The mean qualitative and quantitative scores of toxic lesions for free doxorubicin and entrapped in negative liposomes are 2.7 and 2.23, respectively. However, the mean score for the group of mice treated with positive liposomes is only 1.12, showing a better than 2-fold scoring protection of both the extent and severity of cardiac lesions.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7066898

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Cardiotoxicity of doxorubicin and other anthracycline derivatives.

Authors:  D Jain
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

Review 2.  Minimising the long-term adverse effects of childhood leukaemia therapy.

Authors:  Claudia Langebrake; Dirk Reinhardt; Jörg Ritter
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution.

Authors:  P A Steerenberg; G Storm; G de Groot; A Claessen; J J Bergers; M A Franken; Q G van Hoesel; K L Wubs; W H de Jong
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 4.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

5.  Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes.

Authors:  A Rahman; A Fumagalli; B Barbieri; P S Schein; A M Casazza
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Interaction of liposome-associated all-trans-retinoic acid with squamous carcinoma cells.

Authors:  R Parthasarathy; P G Sacks; D Harris; H Brock; K Mehta
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Encapsulation of adriamycin in human erythrocytes.

Authors:  A De Flora; U Benatti; L Guida; E Zocchi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

8.  Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes.

Authors:  A Rahman; A Ganjei; J R Neefe
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin.

Authors:  Hongyong Zhang; Yuanpei Li; Tzu-Yin Lin; Kai Xiao; Ashraf S Haddad; Paul T Henderson; Brian A Jonas; Mingyi Chen; Wenwu Xiao; Ruiwu Liu; Kit S Lam; Chong-xian Pan
Journal:  Nanomedicine (Lond)       Date:  2014-03-17       Impact factor: 5.307

Review 10.  Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.

Authors:  Atiar M Rahman; Syed Wamique Yusuf; Michael S Ewer
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.